TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02988752

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Mobile Device
Description: Measure C/D Ratio With An Equipment Attached To A Ophthalmoscope That Will Determine C/D Ratio Without Touching Patient's Eyes. To Perform It We Need Mydriatic Conditions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optical Coherence Tomography
Description: Measure C/D Ratio With OCT, Considered Gold Standard Equipment
Study: NCT03769129

Intervention type: PROCEDURE
Group type: OTHER
Intervention: microwave ablation
Description: microwave ablation
Study: NCT01896921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch to Maraviroc + Raltegravir or Dolutegravir
Description: Change HIV-infected patients on stable, suppressed ART regimens for at least 1 year to experimental regimen of Maraviroc + Raltegravir or Dolutegravir for 48 weeks
Study: NCT05234645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kefir consumption
Description: Following confirmation of eligibility and the provision of informed consent, recruited participants were provided with a 4-week supply of kefir (Live Kefir Company, Pontefract, UK) being instructed to consume 150ml of Kefir per day for the whole 4-week period. No break periods of kefir consumption were offered to any of the participants. In addition, they were instructed to not change their usual dietary habits and exercise routine for the study duration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kefir consumption
Description: Following confirmation of eligibility and the provision of informed consent, recruited participants were provided with a 4-week supply of kefir (Live Kefir Company, Pontefract, UK) being instructed to consume 150ml of Kefir per day for the whole 4-week period. No break periods of kefir consumption were offered to any of the participants. In addition, they were instructed to not change their usual dietary habits and exercise routine for the study duration.
Study: NCT03824522

Intervention type: BIOLOGICAL
Intervention: ADYNOVATE
Description: Pegylated recombinant human factor VIII
Study: NCT01372787

Intervention type: PROCEDURE
Intervention: Assessment of Therapy Complications
Description: Ancillary studies

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Ancillary studies

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01868009

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA
Description: Novel dry powder inhaler (placebo) with 30 doses (2 strips with 30 blisters per strip)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA
Description: Novel dry powder inhaler (placebo) with 30 doses (2 strips with 30 blisters per strip)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DISKUS
Description: Multidose dry powder inhaler (placebo) containing a foil strip worth 60 blisters (1 strip with 60 blisters per strip)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DISKUS
Description: Multidose dry powder inhaler (placebo) containing a foil strip worth 60 blisters (1 strip with 60 blisters per strip)
Study: NCT02060461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FS200 femtosecond laser LASIK

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IntraLase femtosecond laser LASIK
Study: NCT00981981

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 3g medium MW
Description: 21.1g of ready to eat cereal containing 6g total fiber and 3g oat beta glucan with a medium molecular weight

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 4g low MW
Description: 28.7g ready to eat cereal containing 8g total dietary fiber and 4g oat beta glucan with low molecular weight
Study: NCT02916173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Chorionic Gonadotrophin
Description: 250 unit intramuscular
Study: NCT02155218

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Injection Rate
Description: Normally an IV is placed in an arm and the gadolinium contrast (30-40 cc, depending on patient size) is administered through the IV with a power injector as a single bolus. Subjects will have a test bolus and main bolus.
Study: NCT02916173

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human chorionic gonadotrophin + gonadotrophin releasing hormone agonist
Description: 250 unit intramuscular + 1 mg subcutaneous
Study: NCT02943408

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: person-centered mental health intervention
Description: We anticipate that the PCMHI will be comprised of three, one-hour sessions offered over three to six weeks, scheduled at the participants' preference. Sessions will be one-on-one and the peer support specialist interventionist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: health and wellness
Description: The control condition will be an educational health and wellness intervention for stress related disorders that will match the experimental condition for time and attention. The control condition will be three, one hour, individual sessions covering the symptom cycle, managing stress, and identifying social supports.
Study: NCT02784483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200mg via IV infusion)
Description: Patients will get atezolizumab every 21 days for up to 1 year
Study: NCT02559336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated palliative oncology care
Description: Integrated palliative care and oncology care for advanced cancer patients who have an unplanned admission to hospital
Study: NCT00886340

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced standard care
Description: One appointment with nurse practitioner (20 minutes) One appointment with nutritionist (45 minutes)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: Enhanced standard care Six appointments with nurse practitioner (20 minutes)
Study: NCT05858697

Intervention type: OTHER
Intervention: Declining participation in the Aarhus intervention
Description: Each year a fraction of the children invited into the Aarhus intervention decline to participated.

Intervention type: BEHAVIORAL
Intervention: Participation in the Aarhus intervention
Description: A community-based multicomponent family-centered lifestyle intervention which included visits at home and weekly supervised physical activity. The intervention has a maximum duration of one year.
Study: NCT02939040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Activities
Description: The PPB intervention involves noting at least one positive event each day, writing it down on a slip of paper and then depositing this piece of paper in a piggy bank. This practice is to take place at the end of the day, every day over a circumscribed period of time. At the end of the deposit period the participant closes the account and makes a full withdrawal by taking all of the slips out of the piggy bank and reading each one the night before surgery.
Study: NCT02502812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clop F2
Description: A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clop F2
Description: A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
Study: NCT03653455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Email reminders
Description: Patients will receive email reminders until their PROs are completed.
Study: NCT03653455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Email reminders
Description: Patients will receive email reminders until their PROs are completed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Email reminders
Description: Patients will receive email reminders until their PROs are completed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre- and Post-operative discussion
Description: Patients will discuss with their provider the importance of PROs pre-operatively, as well as their post-operative progression in comparison to established norms.
Study: NCT01797471

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Lattice Extreme Ablative Dose (LEAD) Radiation Therapy
Description: A single fraction of LEAD RT, dose of 18 Gy will be delivered to subjects on day 1
Study: NCT02755480

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultralow Dose Thoracic Computed Tomography
Description: Ultralow dose chest CT (uLDCTT) at a radiation dose comparable to 2 chest X-rays
Study: NCT04741035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified sternal precautions
Description: Use pain and discomfort to guide the safe use of the arms Avoid pushing or pulling with one arm Use both arms close to the body during lifting Use of arms is possible, but keep them close to the body Avoid stretching one or both arms backwards at the same time Use a cushion or perform sternal preservation technique (crossing the arms in a 'self-hugging 'posture) when coughing.~When transferring, roll onto the side, ease the legs over the edge of the bed and carefully use the arms to sit up from a lying position

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional sternal precautions
Description: Avoid pushing or pulling through the arms Avoid one-arm (unilateral) activity Limit the elevation of the arms to 90 degrees Avoid lifting objects heavier than 2 kg Use a cushion or perform sternal preservation technique (crossing the arms in a 'self-hugging' posture) when coughing Limit the use of the arms when transferring from sitting to standing and getting out of bed Avoid placing the arms behind the back
Study: NCT04096391

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flowonix Prometra® II Programmable Infusion System
Description: The Flowonix Prometra® II Programmable Infusion System consists of an implanted infusion pump and catheter, and external components including a clinician programmer, refill and catheter access port kits, the PTC™(a subject operated controller).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pain Medicine
Description: Injections, spinal cord stimulation, peripheral nerve stimulation, pain medication, etc.
Study: NCT03895099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel early follicular phase
Description: Start of ovarian stimulation in early follicular phase
Study: NCT03653455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive
Description: Patients will receive up to $30 in amazon gift cards upon the completion of their PROs.
Study: NCT03455374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with CSI atherectomy device
Description: Following peripheral angiography, patients with significant SFA or below the knee artery disease (≥ 50%) or total occlusions (100%) will have a baseline OCT imaging of the target vessel and the lesion be treated with proper size CSI burr. Repeat OCT imaging will be performed after CSI. Drug eluting balloon angioplasty may be performed in discretion of the operator. If DEB is used, a final OCT imaging will be performed to assess lesion expansion and possible dissections. Balloon sizing will be based on 1:1 vessel ratio with the length covering from minimally diseased distal segment to minimally diseased proximal segment. We will try to avoid use of stents.
Study: NCT00833560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: In Part 1, cyclophosphamide with dose ranging from 900 to 1500 mg will be administered intravenously on Day 1 of each 21 day cycle for 3 cycles to determine optimal dose. In Part 2, optimal dose determined in Part 1 will be administered on Day 1 of each 21 day cycle for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.3 mg/m2 will be administered intravenously on Days 1,4,8, and 11 of each 21 day cycle for 3 cycles in both parts (Part 1 and Part 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants will receive dexamethasone 40 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21 day cycle for 3 cycles in both parts (Part 1 and Part 2).
Study: NCT03895099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel medium follicular phase
Description: Start of ovarian stimulation in medium follicular phase
Study: NCT02555540

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix
Description: Randomised assignment

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix
Description: Randomised assignment
Study: NCT03895099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel ovulatory phase
Description: Start of ovarian stimulation in ate follicular phase
Study: NCT03895099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel late follicular phase
Description: Start of ovarian stimulation in ovulatory Phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel luteal phase
Description: Start of ovarian stimulation in luteal phase
Study: NCT00682383

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta
Description: Cisplatin 75 mg/m2 day 1 and 22~Etoposide 80mg/m2 days 1-3, 22-24~Radiation therapy: (initial fields 1.8gy/day (5 weeks) to 45Gy, then boost 2.0Gy/day (8 days) to a total of 61Gy) beginning day 1 (Total elapsed time: approximately 6 weeks, 3 days)~Filgrastim 5µg/kg\* SQ injection days 4-13 and days 25-34~Docetaxel 75mg/m2 Q 3 Weeks X 3 Cycles~Pegfilgrastim 6 mg SQ injection day 2 of each cycle
Study: NCT00112489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study: NCT02502812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clop F2
Description: A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
Study: NCT00112489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study: NCT02783391

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECoG and intracortical electrodes
Study: NCT02502812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clop F2
Description: A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Innovator
Description: A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Innovator
Description: A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Innovator
Description: A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Innovator
Description: A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
Study: NCT02555540

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix
Description: Randomised assignment

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix
Description: Randomised assignment

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix
Description: Randomised assignment

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix
Description: Randomised assignment

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saline)
Description: Randomised assignment

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saline)
Description: Randomised assignment
Study: NCT02502812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Innovator
Description: A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Innovator
Description: A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
Study: NCT02454465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy group
Description: Six week, Acceptance and Commitment Therapy group for those with adjustment difficulties following an acquired/traumatic brain injury or other neurological condition.
Study: NCT03033862

Intervention type: DEVICE
Intervention: Bioresorbable Vascular Scaffold
Description: Bioresorbable Vascular Scaffold

Intervention type: DEVICE
Intervention: Drug Eluting Stent
Description: Drug Eluting Stent
Study: NCT02527434

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab monotherapy
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4736 monotherapy
Description: IV infusion
Study: NCT02555540

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saline)
Description: Randomised assignment

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saline)
Description: Randomised assignment
Study: NCT02155218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Tailored Injection Rate
Description: Normally an IV is placed in an arm and the gadolinium contrast (30-40 cc, depending on patient size) is administered through the IV with a power injector as a single bolus. Subjects will have a test bolus and main bolus. We will use a mathematical algorithm to rapidly analyze the test bolus and calculate a predicted best way to inject the main bolus - likely slower and multi-phasic, meaning different flow rates as the bolus injection evolves.
Study: NCT02527434

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4736 + tremelimumab combination therapy
Description: IV infusion
Study: NCT01551914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic Scissors (Ethicon)
Description: Haemostasis using Ultrasonic scissors

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar Electrosurgical instruments (Medtronic) (SLS- Clips)
Description: bipolar, monopolar or clip coagulation techniques
Study: NCT03092778

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: A computed tomography (CT) scan will be completed to map out where to insert the cryoablation needle. Numbing medicine will be used to numb the skin and deeper tissues before inserting the needle.~The cryoablation needle will be inserted and directed toward the target area of the vagal nerve. A CT scan will be done during the procedure to help guide the needle which will be held in position by the study doctor(s) once it reaches the target area. With the needle in place, the study doctor(s) will freeze the zone over 3 minutes, a 2 minutes thaw will follow, then 2 more cycles of 3 minutes freeze and 2 minute thaw will complete the procedure. This portion of the procedure can last from 25 to 35 minutes. Once the targeted area has been properly treated, the cryoablation needle will be withdrawn.
Study: NCT01767597

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ELISA testing
Description: Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg) and anti-HBsAg antibody (anti-HBs Ab) status. Results will be given after test results are available (8-10 days).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ELISA testing
Description: Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg) and anti-HBsAg antibody (anti-HBs Ab) status. Results will be given after test results are available (8-10 days).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid testing
Description: A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®) and anti-HBs antibody status (anti-HBs Ab, using Quick ProfileTM). Results will be given the same day.
Study: NCT01977430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide and furosemide
Description: This clinical trial is cross-over study. The diuretic arm's patients will receive combined diuretic treatment for 1 month: 20 mg of furosemide three times daily and 50 mg of hydrochlorothiazide twice daily
Study: NCT04346667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine Sulfate Regular dose
Description: Hydroxychloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate Loading Dose
Description: Hydroxychloroquine administered as a loading dose only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Chloroquine administered based off of in-vitro pharmacokinetics study of optimal dosage for efficacy against SARS-CoV-2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard of Care plus placebo
Study: NCT05591976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training program
Description: 16-week, structured exercise training program including resistance and aerobic exercise
Study: NCT03382626

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: anodal tDCS
Description: Anodal tDCS will be applied on the left prefrontal cortex dorsolateral (F3 area using International 10-20 system for EEG electrode placement) with the following parameters: electrode size of 25-35 cm², 2mA, 0.057 mA/cm² and duration of 20 minutes. The cathode will be placed over the supra-orbital region.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Computer-assisted training
Description: The computer-assisted cognitive training will consist of games with visual and auditory stimuli to improve working memory, attention, and executive function. The games will be Genius and Labyrinth games, reaction time and timing-coincident.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Computer-assisted training
Description: The computer-assisted cognitive training will consist of games with visual and auditory stimuli to improve working memory, attention, and executive function. The games will be Genius and Labyrinth games, reaction time and timing-coincident.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Sham tDCS will be applied with the same parameters and electrode placement of active anodal tDCS. However, the current flow will be interrupted by the device after few seconds.
Study: NCT01423435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRK-100STP
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRK-100STP
Description: oral